Life sciences software provider CambridgeSoft Corporation, US, has announced that it has completed a private equity investment by Health Evolution Partners and a follow-on investment by Goldman Sachs. In connection with the investment, Adam Grossman will represent Health Evolution Partners on the CambridgeSoft Board of Directors. Raheel Zia, vice president of Goldman Sachs, will continue serving on the Board, based upon Goldman Sachs’ original investment in 2008.
CambridgeSoft noted that its software as a service (SaaS) cloud computing offerings have continued to gain broad customer acceptance, beyond their initial launch almost five years ago. Users of CambridgeSoft’s ChemBioOffice Cloud benefit by joining a growing community of customers who share infrastructure and IT costs, resulting in lower management overhead, little up-front investment and immediate access to the full range of the latest, scientist-tested ChemBioOffice Enterprise applications.
CambridgeSoft is a supplier of discovery, collaboration, and knowledge management research IT enterprise solutions, desktop software, scientific databases and consulting services for the pharmaceutical, biotechnology, and chemical industries. Its integrated product suite seeks to improve the productivity of researchers in the discovery, development and commercialisation of chemical and biological compounds. Products include Cloud, Enterprise, Workgroup and Desktop versions of Chem & Bio Office, including Chem & Bio Draw and E-Notebook, providing knowledge management, chemical and biological informatics, and scientific database solutions.
Search for more such software solutions in K-Store
Discuss this NEWS
